FDA Approves AstraZeneca Pill for Treating Advanced Breast Cancer
· Telemundo McAllen (KTLM)
The FDA has approved AstraZeneca's drug, camizestrant, for treating advanced breast cancer in adults. Marketed as Etcamah, this medication received accelerated approval to address serious conditions. It targets patients with ESR1 gene mutations, which hinder responses to common hormonal therapies like aromatase inhibitors. Patients will need to take Etcamah alongside a CDK4/6 inhibitor, such as Verzenio, Kisqali, or Ibrance. The FDA requires the Guardant360 CDx test to confirm eligibility for the drug. Clinical trials showed that Etcamah extended progression-free survival by 16 months, but there are warnings about potential heart rhythm issues and risks to fetuses when combined with certain medications.
AI summary · Source: Telemundo McAllen (KTLM) →
